Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.

Inclusion Criteria:

• Participants must have histologic confirmation of advanced (metastatic, recurrent, and/or unresectable) squamous cell carcinoma of the head and neck (SCCHN), nonsmall cell lung cancer (NSCLC), or renal cell cancer (RCC) with measurable disease per RECIST 1.1
• Participants expected to have received standard of care therapies including an available PD-(L)1 inhibitor
• Eastern cooperative oncology group performance status of 0 or 1
• Women of childbearing potential must agree to follow methods of contraception

Exclusion Criteria:

• Participants with active, known or suspected autoimmune disease
• Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
• Uncontrolled or significant cardiovascular disease
• History of or with active interstitial lung disease or pulmonary fibrosis
• Prior participation in anti-natural killer cell receptor (anti-NKG2A) clinical study
• History of allergy or hypersensitivity to study drug components

Other protocol-defined inclusion/exclusion criteria apply